Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Triple Negative Breast Neoplasms × avelumab × Clear all

Phase

Status

Terminated 3 Recruiting 3 Withdrawn 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Transitional Cell 4 Urinary Bladder Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Merkel Cell 2 Breast Neoplasms 2 Ureteral Neoplasms 1 Triple Negative Breast Neoplasms 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myeloid, Acute 1 Kidney Neoplasms 1 Chordoma 1

Interventions

Paclitaxel 8 pembrolizumab 7 Doxorubicin 5 Cyclophosphamide 4 Carboplatin 4 130-nm albumin-bound paclitaxel 4 durvalumab 3 olaparib 2 glembatumumab vedotin 2 Radiotherapy 2 Albumin-Bound Paclitaxel 2 yeast-CEA vaccine 1 trifluridine tipiracil drug combination 1 tremelimumab 1 trastuzumab duocarmazine 1 tislelizumab 1 taxane 1 talazoparib 1 sacituzumab govitecan 1 sabizabulin 1 parsaclisib 1 mirvetuximab soravtansine 1 liposomal doxorubicin 1 irinotecan sucrosofate 1 eribulin 1 brigimadlin 1 bavituximab 1 avelumab 1 atezolizumab 1 X-Rays 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03554109 2025-02-21

TNBC

ImmunityBio, Inc.

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡